← SynDRA
VALGANCICLOVIR
SynDRA canonical compound SYN0023529 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Approval status | Approved · Rx/OTC |
| Mechanism of action | DNA synthesis inhibitor |
| Indication | cytomegalovirus (CMV) |
| Disease area | infectious disease |
All known targets
- HSV UL30
- TK
- GRM1
- GRM5
- UL26
- VCP
- punA
Mechanisms of action (all sources)
- DNA synthesis inhibitor
- HSV UL30 INHIBITOR
- DNA polymerase inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- PDE3A
- ADORA1
- NR3C1
- HTR2A
- HTR2B
- HTR2C
- HTR3A
- KCNH2
- MAOA
- MC3R
- MC4R
- MLNR
- NPY1R
- NR1I2
- OPRD1
- HRH3
- OPRK1
- OPRM1
- PDE4D
- PGR
- PTGS2
- SLC29A1
- SLC6A2
- SLC6A3
- SLC6A4
- TBXA2R
- HTR1A
- HRH2
- ADORA2A
- CCKAR
- ADORA3
- ADRA1A
- ADRA2A
- ADRA2B
- ADRA2C
- ADRB1
- ADRB2
- AGTR1
- AVPR1A
- AVPR2
Drug classes
- DNA Polymerase Inhibitors
- Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor
- Anti-Infective Agents
- Antiviral Agents
- Nucleoside Analog Antiviral
- Nucleic Acid Synthesis Inhibitors
ATC classes
- J05A · DIRECT ACTING ANTIVIRALS
- S01A · ANTIINFECTIVES
Cross-references
Synonyms
- VALCYTE
- VALGANCICLOVIR HYDROCHLORIDE
- Valcyte
- valganciclovir hydrochloride
- valganciclovir HCl
- Cymeval
- RS 79070
- RO1079070/194
- Valcyte (TN)
- Valganciclovir (INN)
- Valganciclovir (Oral)
- Valganciclovir [INN:BAN]
- L-Valine, ester with ganciclovir
- GCU97FKN3R
- CHEBI:63635
- valganciclovirum
- RefChem:56199
- Ganciclovir L valyl Ester
- DTXCID3028263
- J05AB14
- VALGANCICLOVIR [INN]
- NCGC00168779-01
- UNII-GCU97FKN3R
- HSDB 8085
- RS-79070
- VALGANCICLOVIR [MI]
- SCHEMBL28996
- SCHEMBL28998
- VALGANCICLOVIR [VANDF]
- GTPL4716
- orb1688778
- VALGANCICLOVIR [WHO-DD]
- SCHEMBL12672612
- GLXC-22223
- HY-A0032
- EBC-26707
- AKOS015896083
- AKOS015966553
Reported adverse events
- TEN
- Insomnia
- Nausea
- Pyrexia
- Tremor
- Vomiting
- Headache
- Neutropenia
- Retinal detachment
- Thrombocytopenia
- Abdominal pain
- Agranulocytosis
Look up VALGANCICLOVIR in the interactive SynDRA portal →